Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
The company will host an earnings conference call at 8:00 AM Eastern Time; registration is required for participants who wish to ask questions and an audio-only webcast will be available on the investor website.
Details
News Market Reaction – HBIO
On Feb 26, the day this news came out, HBIO closed 0.46% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Q4 2025 earnings date
- March 12, 2026
- Scheduled results release before market open
- Earnings call time
- 8:00 AM ET
- Q4 2025 conference call start time
- Prelim Q4 2025 revenue
- $23.7M
- Preliminary results reported on 2026-02-10
- Prelim gross margin
- 60%
- High end of 58–60% guidance range
- Prelim adjusted EBITDA
- $3.8M
- Q4 2025 preliminary adjusted EBITDA
- EBITDA YoY growth
- 27%
- Year-over-year growth in preliminary Q4 2025 adjusted EBITDA
- Registered resale shares
- 9,500,000 shares
- S-3 resale registration for existing securityholders
- Warrant exercise proceeds
- $1.0M
- Maximum cash proceeds if all $0.50 warrants exercised
Previous Conferences,earnings Reports
-
Set Q3 2025 results release and call details before market open.
-
Announced Q2 2025 earnings date and 8:00 AM ET conference call.
-
Scheduled Q1 2025 results release and earnings conference call.
-
Announced Q4 2024 results timing and associated conference call.
-
Set Q3 2024 earnings release and call plans before market open.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.